Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

• Strategic Collaboration: Telix Pharmaceuticals announced Letters of Intent (LOIs) to collaborate with EDAP TMS S.A. and Profound Medical Corp.
• Integration Focus: Partnerships aim to integrate Telix’s PSMA-PET imaging agents (Gozellix®, Illuccix®) with Profound’s minimally invasive ablation technologies (TULSA-PRO).
• Clinical Objective: Utilize molecular imaging for patient selection, treatment planning, and post-treatment monitoring in prostate cancer care.
• Scope: Non-promotional scientific, educational, and research engagement; no immediate revenue terms disclosed.
• Contextual Alignment: Follows Profound’s Q1 2026 earnings (May 7) showing $5.3M revenue (+104% YoY) and CAPTAIN trial safety data release (March 2026).
• Headline Discrepancy: While the headline attributes the announcement to Telix, the content explicitly details Profound’s involvement in the workflow integration, impacting both entities.

• Positive Strategic Validation: The collaboration confirms the clinical utility of combining PSMA-PET imaging with TULSA ablation, reinforcing the "theranostic" narrative established by CAPTAIN trial safety data.
• Revenue Uncertainty: LOIs are non-binding and lack specific financial terms or revenue guarantees; impact on immediate top-line growth is negligible compared to Q1 earnings guidance.
• Market Expectation: Given the strong clinical data release in March 2026, strategic partnerships were anticipated by investors to drive adoption; thus, this news is largely priced-in rather than a surprise catalyst.
• Risk of Dilution/Execution: No immediate capital raise mentioned in this specific release, but reliance on third-party partners (Telix, EDAP) introduces execution risk regarding integration timelines and regulatory approvals for combined workflows.
• Rating Justification: Classified as Routine - Positive because it supports the existing growth thesis without altering the fundamental valuation model or providing immediate cash flow certainty.

• Company: Profound Medical Corp. (NASDAQ: PROF / TSX: PRN).
• Flagship Project: TULSA-PRO® system for MRI-guided, incision-free prostate ablation.
• Secondary Platform: Sonalleve® for uterine fibroids and pain palliation (CE marked, FDA 510(k) cleared).
• Technology: AI-powered, robotically controlled directional ultrasound with real-time MR thermography.
• Regulatory Status: TULSA-PRO cleared in US, Europe, Canada, Saudi Arabia, India, Australia/NZ; Sonalleve approved for multiple indications globally.
• Clinical Milestones: CAPTAIN trial met primary safety endpoint (March 2026); Level 1 post-market study comparing TULSA to robotic radical prostatectomy.